Recon: FDA staff raise concerns over Spectrum’s cancer drug ahead of adcomm; EMA calls for biosimilar interchangeability in EU

ReconReconBiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy